Telo Genomics Corp. (TDSGF)

[Bassman101]

http://bit.ly/2sxoIMc

Exciting Digital Health Company to Keep an Eye On

Startup Spotlight by PM360 Staff on June 17th, 2017

Bioinformatix Datablend Wearables 3D Signatures Epilen GalileoMD Spring

3D Signatures
Jason Flowerday, CEO and Director
[e-mail]
www.3dsignatures.com
About:
3D Signatures Inc. has developed proprietary software that analyzes a patient’s chromosomal arrangement—or signature—through a non-invasive blood test or tissue sample, measuring disease stage and genomic stability, as well as drug efficacy and potential side effects. Unlike most diagnostic companies, the platform tells doctors how to personalize treatment and best manage the disease for each individual patient.
Transformational:

3D Signatures is preparing to market its imaging technology once late-round clinical trials fully confirm its reliability for Hodgkin’s disease. Currently, no biomarker is available that can predict patient response to standard chemotherapy in Hodgkin’s lymphoma patients and thereby help guide treatment decisions on the individual basis.
Offering:

3D Signatures’ validation program for its Hodgkin’s lymphoma (“HL”) test (“Telo-HL”) validation program consists of five stages which aim to develop a commercially marketable laboratory-developed test (LDT) within the next 10 months. In parallel to this, the company is working on validating four more products to address lung cancer, prostate cancer, multiple myeloma, and Alzheimer’s disease.

Big Picture:

The global cancer diagnostics market is expected to reach $13.1 billion by 2020, according to MarketsandMarkets, one of the world’s largest research firms. What sets 3D Signatures apart is that it’s the only company in the world conducting 3D telomere analysis. Unlike 2D analysis, 3D Signatures is able to accurately measure genomic instability. This technology harnesses the predictive power of the telomere as a dynamic biomarker. The company can determine how a disease will progress and enables clinicians to measure the appropriateness and effectiveness of different treatments for specific patients—saving time and improving outcomes.